Halozyme Therapeutics Sees FY23 EPS $2.65-$2.75 VS $2.61 Est; Revenue $825M-$845M Vs $823.06M Est
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics has projected its FY23 EPS to be between $2.65 and $2.75, surpassing the estimated $2.61. The company also expects its revenue to be between $825M and $845M, slightly above the estimated $823.06M.
August 08, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics' FY23 EPS and revenue forecasts exceed estimates, which may positively impact its stock price.
Halozyme Therapeutics' higher than expected FY23 EPS and revenue forecasts indicate strong financial performance, which is likely to boost investor confidence and potentially drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100